Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States

Apr 1, 2017, 00:00
10.1016/j.jval.2017.01.007
https://www.valueinhealthjournal.com/article/S1098-3015(17)30067-0/fulltext
Title : Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30067-0&doi=10.1016/j.jval.2017.01.007
First page : 602
Section Title : Economic Evaluation
Open access? : No
Section Order : 10

Objectives

To determine the adjusted incremental total costs (direct and indirect) for patients (aged 3–17 years) with attention-deficit/hyperactivity disorder (ADHD) and the differences in the adjusted incremental direct expenditures with respect to age groups (preschoolers, 0–5 years; children, 6–11 years; and adolescents, 12–17 years).

Methods

The 2011 Medical Expenditure Panel Survey was used as the data source. The ADHD cohort consisted of patients aged 0 to 17 years with a diagnosis of ADHD, whereas the non-ADHD cohort consisted of subjects in the same age range without a diagnosis of ADHD. The annual incremental total cost of ADHD is composed of the incremental direct expenditures and indirect costs. A two-part model with a logistic regression (first part) and a generalized linear model (second part) was used to estimate the incremental costs of ADHD while controlling for patient characteristics and access-to-care variables.

Results

The 2011 Medical Expenditure Panel Survey database included 9108 individuals aged 0 to 17 years, with 458 (5.0%) having an ADHD diagnosis. The ADHD cohort was 4.90 times more likely (95% confidence interval [CI] 2.97–8.08; P 0.001).

Conclusions

Early diagnosis and use of evidence-based treatments may address the substantial burden of ADHD.

Categories :
Tags :
  • attention-deficit/hyperactivity disorder
  • children
  • cost of illness
  • health care costs
Regions :
ViH Article Tags :